e-Therapeutics plc' ETS2101 Enters Phase I Clinical Trial in Brain Cancer  
6/19/2012 10:48:51 AM

OXFORD & NEWCASTLE, England & SAN DIEGO--(BUSINESS WIRE)--e-Therapeutics plc (AIM: ETX) announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.